Therefore, we propose that anti-β2-M Ab is a promising agent in aggressive prostate cancer bone metastatic patients and therefore combination treatment with the antibody and radiation will reduce tumor burden in such patients. This evidence concerns the gene B2M and Familial prostate cancer.